CD27-Binding Agents With CD40/CD137 Costimulatory Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved antibody-based immunotherapies with increased agonism and/or potency to engage CD27 in combination therapy with other immunomodulatory antibodies for treating cancer.
Innovation Solution
A combination therapy using a first binding agent that binds to CD27 and a second binding agent that binds to both CD40 and CD137 to enhance anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional single-agent immunotherapy is used, then treatment simplicity is maintained, but antitumor activity and immune response potency are insufficient
Solution Approach 1:
The patent combines multiple immunomodulatory binding agents into a single composition, where one binding agent targets CD27 and another binding agent targets either PD-1, PD-L1, or CTLA-4. This merging of multiple therapeutic agents into one formulation maintains treatment simplicity while achieving synergistic antitumor effects that exceed the potency of single-agent therapy.
2Reliability
If combination therapy with multiple binding agents is used, then antitumor activity and immune response are enhanced, but treatment complexity increases
Solution Approach 1:
Multiple binding agents with different mechanisms of action are combined into a single pharmaceutical composition, enabling administration of complex combination therapy through a single dosing regimen. This approach maintains ease of operation by avoiding the need for separate administrations of multiple agents while achieving enhanced immune response potency through synergistic interactions between the binding agents.
3Reliability
If conventional immunotherapy is used, then treatment simplicity is maintained, but costimulatory signaling and T-cell activation are insufficient
Solution Approach 1:
The patent merges a binding agent that provides costimulatory signaling through CD27 engagement with binding agents that block inhibitory checkpoints (PD-1, PD-L1, or CTLA-4). This combination achieves robust T-cell activation by simultaneously providing costimulation and removing inhibitory signals, overcoming the insufficiency of conventional immunotherapy while managing mechanism complexity through a coordinated multi-target approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy enhances CD27 activation, leading to increased antitumor activity and improved immune response against cancer.
Implementation Method 1
a first binding agent comprising at least one binding region binding to CD27
Implementation Method 2
a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137
Data Source
AI summary
The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.